Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | REGN4018 |
Synonyms | |
Therapy Description |
REGN4018 is a bispecific antibody that binds MUC16 (CA125) on tumor cells and CD3 on T-cells to stimulate T-cell killing of MUC16-expressing tumor cells (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1777, PMID: 31217340). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
REGN4018 | REGN-4018|REGN 4018|Ubamatamab | CD3 Antibody 86 MUC16 Targeted Therapy 8 | REGN4018 is a bispecific antibody that binds MUC16 (CA125) on tumor cells and CD3 on T-cells to stimulate T-cell killing of MUC16-expressing tumor cells (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1777, PMID: 31217340). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03564340 | Phase Ib/II | Cemiplimab + REGN4018 REGN4018 | Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Platinum-Resistant Ovarian Cancer | Recruiting | USA | ITA | GBR | FRA | ESP | BEL | AUS | 3 |